These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 37755647)

  • 1. Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors.
    He R; Weng Z; Liu Y; Li B; Wang W; Meng W; Li B; Li L
    Stem Cell Rev Rep; 2023 Nov; 19(8):2557-2575. PubMed ID: 37755647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer cells as a new source of induced pluripotent stem cells.
    Shamsian A; Sahebnasagh R; Norouzy A; Hussein SH; Ghahremani MH; Azizi Z
    Stem Cell Res Ther; 2022 Sep; 13(1):459. PubMed ID: 36064437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell Reprogramming Techniques: Contributions to Cancer Therapy.
    Guo T; Wei Q
    Cell Reprogram; 2023 Aug; 25(4):142-153. PubMed ID: 37530737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overlapping genes may control reprogramming of mouse somatic cells into induced pluripotent stem cells (iPSCs) and breast cancer stem cells.
    Mosca E; Cocola C; Sabour D; Pelucchi P; Bertalot G; Palumbo O; Carella M; Götte M; Schöler HR; Reinbold R; Zucchi I; Milanesi L
    In Silico Biol; 2010; 10(5-6):207-21. PubMed ID: 22430355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induced Pluripotent Stem Cell-Derived T Cells for Cancer Immunotherapy.
    Patel SJ; Yamauchi T; Ito F
    Surg Oncol Clin N Am; 2019 Jul; 28(3):489-504. PubMed ID: 31079802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current progress and potential practical application for human pluripotent stem cells.
    Philonenko ES; Shutova MV; Chestkov IV; Lagarkova MA; Kiselev SL
    Int Rev Cell Mol Biol; 2011; 292():153-96. PubMed ID: 22078961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induced Pluripotent Stem Cells and Induced Pluripotent Cancer Cells in Cancer Disease Modeling.
    Zhu D; Kong CSL; Gingold JA; Zhao R; Lee DF
    Adv Exp Med Biol; 2018; 1119():169-183. PubMed ID: 30069853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induced pluripotent stem cell technology: A window for studying the pathogenesis of acquired aplastic anemia and possible applications.
    Elbadry MI; Espinoza JL; Nakao S
    Exp Hematol; 2017 May; 49():9-18. PubMed ID: 28062362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of induced pluripotent stem cell technology for the investigation of hematological disorders.
    Dolatshad H; Tatwavedi D; Ahmed D; Tegethoff JF; Boultwood J; Pellagatti A
    Adv Biol Regul; 2019 Jan; 71():19-33. PubMed ID: 30341008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential therapeutic applications of differentiated induced pluripotent stem cells (iPSCs) in the treatment of neurodegenerative diseases.
    Gao A; Peng Y; Deng Y; Qing H
    Neuroscience; 2013 Jan; 228():47-59. PubMed ID: 23069758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induced pluripotent stem cell models of myeloid malignancies and clonal evolution.
    Reilly A; Doulatov S
    Stem Cell Res; 2021 Apr; 52():102195. PubMed ID: 33592565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of induced pluripotent stem cell technology.
    Zhou H; Ding S
    Curr Opin Hematol; 2010 Jul; 17(4):276-80. PubMed ID: 20442654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 switches off pluripotency on differentiation.
    Lin T; Lin Y
    Stem Cell Res Ther; 2017 Feb; 8(1):44. PubMed ID: 28241890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status in cancer cell reprogramming and its clinical implications.
    Izgi K; Canatan H; Iskender B
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):371-383. PubMed ID: 27620745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application of iPSC technology to cancer treatment].
    Oshima N; Aoi T
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):139-43. PubMed ID: 25743131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reliable generation of induced pluripotent stem cells from human lymphoblastoid cell lines.
    Barrett R; Ornelas L; Yeager N; Mandefro B; Sahabian A; Lenaeus L; Targan SR; Svendsen CN; Sareen D
    Stem Cells Transl Med; 2014 Dec; 3(12):1429-34. PubMed ID: 25298370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induced pluripotent stem cell modeling of malignant hematopoiesis.
    Chao MP; Majeti R
    Exp Hematol; 2019 Mar; 71():68-76. PubMed ID: 30659850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reprogramming Methods Do Not Affect Gene Expression Profile of Human Induced Pluripotent Stem Cells.
    Trevisan M; Desole G; Costanzi G; Lavezzo E; Palù G; Barzon L
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28117672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The miR-302-Mediated Induction of Pluripotent Stem Cells (iPSC): Multiple Synergistic Reprogramming Mechanisms.
    Ying SY; Fang W; Lin SL
    Methods Mol Biol; 2018; 1733():283-304. PubMed ID: 29435941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A real-time pluripotency reporter for the long-term and real-time monitoring of pluripotency changes in induced pluripotent stem cells.
    Shen HF; Li YL; Huang SH; Xia JW; Yao ZF; Xiao GF; Zhou Y; Li YC; Shi JW; Lin XL; Zhao WT; Sun Y; Tian YG; Jia JS; Xiao D
    Aging (Albany NY); 2022 May; 14(10):4445-4458. PubMed ID: 35575836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.